Table 4.
Patient characteristics, mean %A1C change, and % with clinically important (≥0.5) A1C reduction in intervention and comparison groups
| Intervention | Comparison | p a | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Pre | Post | Difference | ≥0.5 reduction | N | Pre | Post | Difference | ≥0.5 reduction | ||
| M ± SD (range) | M ± SD (range) | M ± SD (range) | % | M ± SD (range) | M ± SD (range) | M ± SD (range) | % | ||||
| Age (years) | 491 | 54.0 ± 12.5 (19.0–85.0) | 82 | 53.1 ± 10.5 (30.0–83.0) | 0.57 | ||||||
| BMI (kg/m2) | 436 | 36.4 ± 9.3 (17.7–74.2) | 64 | 36.8 ± 8.8 (18.7–59.6) | 0.71 | ||||||
| %A1Cb | 416 | 8.7 ± 2.5 (5.0–14.1) | 63 | 8.8 ± 1.7 (5.5–14.1) | 0.68 | ||||||
| %A1C ≥ 7.5 | 204 | 10.0 ± 2.1 (7.5–14.1) | 9.0 ± 2.0 (5.4–14.0) | −1.1 ± 2.4§ (−8.5–5.8) | 51 | 41 | 9.3 ± 1.3 (7.6–13.0) | 8.9 ± 1.7 (5.4–14.0) | −0.4 ± 1.8 (−5.0–3.5) | 46 | 0.003 |
| Site A | 76 | 9.4 ± 1.9 (7.5–14.0) | 8.7 ± 1.8 (5.4–13.10) | −0.8 ± 2.3# (−7.8–3.4) | 45 | 14 | 9.5 ± 1.3 (7.7–12.1) | 9.4 ± 1.9 (6.6–12.6) | −0.1 ± 1.4 (−3.0–2.4) | 36 | 0.92 |
| Site B | 55 | 10.3 ± 2.1 (7.5–14.0) | 9.4 ± 2.1 (6.0–14.0) | −0.9 ± 2.3# (−7.3–5.8) | 60 | 1 | 10.1 | 9.6 | −0.5 | ||
| Site C | 73 | 10.4 ± 2.1 (7.5–14.0) | 8.9 ± 2.0 (5.5–13.70) | −1.5 ± 2.6§ (−8.5–2.4) | 52 | 21 | 9.3 ± 1.4 (7.6–13.0) | 8.3 ± 1.3 (6.1–11.3) | −1.0 ± 1.8 (−5.0–3.0) | 56 | 0.005 |
| Site D | 5 | 8.5 ± 0.7 (7.8–9.6) | 9.7 ± 2.1 (7.5–11.9) | 1.1 ± 1.7 (−0.5–3.5) | 20 | ||||||
Descriptive statistics shown were calculated based on all participants with available data. Differences were calculated for participants who had both pre- and post-intervention data on corresponding variables for each site (i.e., post-intervention %A1C minus pre-intervention %A1C)
§ p < 0.001; # p < 0.01, for tests of change within the group
aA p value for a t test comparing the groups at baseline
bGlycosylated hemoglobin A1C laboratory values reported as percentages, where a 0.5 reduction reflects a clinically significant reduction (e.g., 8.0 to 7.5 %)